A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational Unadjuvanted RSV Maternal Vaccine Compared to Placebo When Administered to Healthy Non-pregnant Women.
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2019
At a glance
- Drugs GSK-3888550A (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 21 Nov 2018 Planned End Date changed from 26 Sep 2019 to 19 Sep 2019.
- 21 Nov 2018 Planned primary completion date changed from 29 Apr 2019 to 22 Apr 2019.
- 21 Nov 2018 Status changed from not yet recruiting to recruiting.